title: [The clinical and prognostic significance of acute myeloid leukemia with FLT3-ITD].
abstract: Objective:To investigate the clinical significance and prognosis factors of acute myeloid leukemia (AML) with FLT3 mutation-internal tandem duplication (FLT3-ITD) and provide more evidence for prognosis evaluation in AML with FLT3-ITD.Methods:The clinical characteristics and outcomes of 98 AML with FLT3-ITD were analyzed.Results:In patients with FLT3-ITD positive AML, the median of WBC and peripheral blood blast at initial diagnosis were 58.2 (0.3-461.8) ×109/L and 42.2 (0-397.1) ×109/L, respectively. The complete remission (CR) rate after one course induction therapy was 60.6% in 71 patients with intermediate or adverse risk. The primary refractory rate was 26.8% in 71 patients with intermediate or adverse risk. The lower number of peripheral blood blast was a favorable factor to achieve CR after one course induction therapy (P=0.009). CR after one course (HR=0.395, 95%CI0.183-0.85,P=0.001) and allo-transplantation in CR1(HR=0.180, 95%CI0.043-0.752,P=0.018) favored longer relapse-free survival (RFS). CR after one course (HR=0.251, 95%CI0.121-0.523,P< 0.001) and lower number of peripheral blood blast (HR=0.219, 95%CI0.088-0.545,P=0.003) favored longer overall survival (OS) in AML with FLT3-ITD.Conclusion:FLT3-ITD positive AML with lower number of peripheral blood blast has a relative favorable prognosis. CR after one course and allotransplantation in CR1are important strategy to improve prognosis in AML with FLT3-ITD.
authors.affiliation: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
authors.forename: D
authors.initials: D
authors.lastname: Lin
authors.forename: H
authors.initials: H
authors.lastname: Wei
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: C L
authors.initials: CL
authors.lastname: Zhou
authors.forename: B C
authors.initials: BC
authors.lastname: Liu
authors.forename: K Q
authors.initials: KQ
authors.lastname: Liu
authors.forename: B F
authors.initials: BF
authors.lastname: Gong
authors.forename: S N
authors.initials: SN
authors.lastname: Wei
authors.forename: G J
authors.initials: GJ
authors.lastname: Zhang
authors.forename: Y T
authors.initials: YT
authors.lastname: Liu
authors.forename: X Y
authors.initials: XY
authors.lastname: Gong
authors.forename: S W
authors.initials: SW
authors.lastname: Qiu
authors.forename: Y C
authors.initials: YC
authors.lastname: Mi
authors.forename: J X
authors.initials: JX
authors.lastname: Wang
mesh_terms: D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism / Q000473:pathology; D009154:Mutation; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D051941:fms-Like Tyrosine Kinase 3